Vanguard Group Inc. Raises Stake in Taysha Gene Therapies, Inc. $TSHA

Vanguard Group Inc. increased its stake in Taysha Gene Therapies, Inc. (NASDAQ:TSHA) by 3.3% during the fourth quarter, according to its most recent filing with the SEC. The fund owned 13,267,805 shares of the company’s stock after buying an additional 418,192 shares during the quarter. Vanguard Group Inc. owned 4.84% of Taysha Gene Therapies worth $72,973,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Marex Group plc purchased a new stake in Taysha Gene Therapies during the second quarter valued at about $29,000. E Fund Management Co. Ltd. purchased a new stake in Taysha Gene Therapies during the second quarter valued at about $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. purchased a new stake in Taysha Gene Therapies during the third quarter valued at about $40,000. Tower Research Capital LLC TRC lifted its holdings in Taysha Gene Therapies by 156.5% during the second quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock valued at $41,000 after purchasing an additional 10,742 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in Taysha Gene Therapies by 51.9% during the second quarter. BNP Paribas Financial Markets now owns 18,591 shares of the company’s stock valued at $43,000 after purchasing an additional 6,350 shares during the last quarter. 77.70% of the stock is owned by hedge funds and other institutional investors.

Taysha Gene Therapies Stock Down 5.5%

TSHA stock opened at $6.30 on Friday. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23. The company’s 50 day moving average is $5.29 and its 200 day moving average is $4.99. The stock has a market cap of $1.81 billion, a price-to-earnings ratio of -16.58 and a beta of 1.25. Taysha Gene Therapies, Inc. has a 1-year low of $2.25 and a 1-year high of $7.30.

Taysha Gene Therapies (NASDAQ:TSHA) last posted its quarterly earnings data on Wednesday, May 6th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). Sell-side analysts predict that Taysha Gene Therapies, Inc. will post -0.48 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on TSHA. Canaccord Genuity Group upped their price objective on shares of Taysha Gene Therapies from $14.00 to $17.00 and gave the company a “buy” rating in a report on Monday, April 6th. Wall Street Zen downgraded shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Needham & Company LLC upped their price objective on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $12.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Two investment analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $11.64.

Insider Buying and Selling at Taysha Gene Therapies

In related news, insider Sukumar Nagendran sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, April 10th. The shares were sold at an average price of $4.46, for a total value of $892,000.00. Following the transaction, the insider directly owned 1,136,410 shares in the company, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 3.78% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.